Immunovant (IMVT) Income towards Parent Company (2018 - 2026)
Immunovant (IMVT) posted Income towards Parent Company of -$147.8 million for Q1 2026, down 33.63% on a QoQ basis from -$110.6 million in Q4 2025, and down 38.88% year-over-year from -$241.9 million in Q1 2025.
Immunovant (IMVT) Income towards Parent Company (2018 - 2026) Analysis & Trends
Immunovant's Income towards Parent Company history runs 9 years deep, the most recent figure standing at -$147.8 million for Q1 2026.
- Quarterly Income towards Parent Company fell 38.88% year-over-year to -$147.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$505.6 million (down 22.17% YoY) and the FY2026 annual result came in at -$505.6 million, down 22.17% from the prior year.
- Income towards Parent Company was -$147.8 million for Q1 2026 at Immunovant, down from -$110.6 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$40.4 million in Q2 2022 and bottomed at -$147.8 million in Q1 2026.
- A 5-year average of -$84.5 million and a median of -$75.3 million in 2024 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2023 — Income towards Parent Company rose 18.68% — and 2024, when it tumbled 116.11%.
- Immunovant's Income towards Parent Company stood at -$63.2 million in 2022, then grew by 18.68% to -$51.4 million in 2023, then tumbled by 116.11% to -$111.1 million in 2024, then grew by 0.44% to -$110.6 million in 2025, then slumped by 33.63% to -$147.8 million in 2026.
- Business Quant data shows IMVT's Income towards Parent Company at -$147.8 million in Q1 2026, -$110.6 million in Q4 2025, and -$126.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Immunovant | 7.17 Bn | 7.17 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -147.84 Mn |
| Dec 31, 2025 | -110.64 Mn |
| Sep 30, 2025 | -126.50 Mn |
| Jun 30, 2025 | -120.61 Mn |
| Mar 31, 2025 | -106.45 Mn |
| Dec 31, 2024 | -111.12 Mn |
| Sep 30, 2024 | -109.12 Mn |
| Jun 30, 2024 | -87.15 Mn |
| Mar 31, 2024 | -75.32 Mn |
| Dec 31, 2023 | -51.42 Mn |
| Sep 30, 2023 | -58.66 Mn |
| Jun 30, 2023 | -73.94 Mn |
| Mar 31, 2023 | -59.43 Mn |
| Dec 31, 2022 | -63.23 Mn |
| Sep 30, 2022 | -47.93 Mn |
| Jun 30, 2022 | -40.37 Mn |
| Mar 31, 2022 | -47.17 Mn |
| Dec 31, 2021 | -41.39 Mn |
| Sep 30, 2021 | -37.70 Mn |
| Jun 30, 2021 | -30.47 Mn |